Qiuqiong Tang
218 Xinghu Street
Suzhou, China
Suzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
NDRG1 expression in cancers confers dependence on DNA damage repair and sensitivity to quinacrine.
Journal: Science signaling
Published: July 21, 2026
AI-aided identification of dual-purpose therapeutic targets PRPF19 and MAPK9 in hepatocellular carcinoma and cellular senescence.
Journal: npj aging
Published: December 02, 2024
AI-Driven Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent.
Journal: Aging and disease
Published: November 15, 2024
Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 25, 2022
FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia.
Journal: Translational oncology
Published: July 10, 2021
MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models.
Journal: Cell death discovery
Published: September 06, 2020
Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.
Journal: Cell & bioscience
Published: August 24, 2019
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Journal: Journal for immunotherapy of cancer
Published: April 23, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026